Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

FDA Grants Olaratumab Priority Review for Soft Tissue Sarcoma

May 4th 2016

The FDA has granted the PDGFRÎ± antagonist olaratumab a priority review for use in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma who are not good candidates for radiotherapy or surgery.

Dr. Demetri on the Evolving Field of Sarcoma

April 27th 2016

George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses the evolving and advancing field of sarcoma.

Rare Sarcomas Pose Significant Hurdles, But Foster Collaboration

April 18th 2016

Damon Reed, MD, discusses the challenges associated with treating rare sarcomas, the importance of collaboration, advancements in the field, and the potential for immunotherapy in the disease.

CHMP Recommends Approval of Eribulin for Advanced Liposarcoma

April 5th 2016

Eribulin mesylate (Halaven) has received a positive recommendation from the EMAâ€™s Committee for Medicinal Products for Human Use as a treatment for patients with advanced or unresectable liposarcoma following prior treatment with an anthracycline-based chemotherapy.

The Future of Sarcoma: Nanotechnology, Immunotherapy, and Shark Research

March 29th 2016

H. Thomas Temple, MD, explains where he sees the future of sarcoma going and what diagnostic technologies and therapeutic advancements he is most excited about.

Trabectedin Offers Third-Line Option in Uterine Leiomyosarcoma

March 24th 2016

Martee L. Hensley, MD, discusses what lies ahead for the treatment paradigm of uterine leiomyosarcoma

Eribulin Liposarcoma Approval Advances Precision Medicine in Oncology

March 23rd 2016

George Demetri, MD, discusses the impact of the eribulinâ€™s FDA approval, what oncologists can learn from studying liposarcoma, and the challenges that come with treating a rare disease.

Trabectedin Significantly Slows Progression in Uterine Leiomyosarcoma

March 20th 2016

Treatment with trabectedin significantly improved progression-free survival compared with dacarbazine in women with advanced uterine leiomyosarcoma, according to a subgroup analysis of the phase III SAR-3007 trial.

Dr. Tap on Olaratumab in Patients With Soft Tissue Sarcoma

March 18th 2016

William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the mechanism of action of olaratumumab as a treatment for patients with soft tissue sarcoma.

Demetri's Team Approach Translates Into Success in Sarcoma Research

February 10th 2016

George D. Demetri, MD, whose teamwork approach has helped pave the way for new drugs for hard-to-treat sarcomas, was honored in the Gastrointestinal Cancer category with a 2014 Giants of Cancer CareÂ® award, a program that the IntellisphereÂ® Oncology Specialty Group launched to honor leaders in the field.

FDA Grants T-Cell Therapy Breakthrough Designation in Sarcoma

February 9th 2016

An affinity enhanced T-cell therapy has received an FDA breakthrough therapy designation for the treatment of patients with inoperable or metastatic pretreated synovial sarcoma who harbor HLA-A*201, HLA-A*205, or HLA-A*206 alleles and whose tumors express the NY-ESO-1 tumor antigen.

FDA Approves Eribulin for Advanced Liposarcoma

January 28th 2016

The FDA has approved eribulin mesylate as a treatment for patients with advanced or unresectable liposarcoma following prior treatment with an anthracycline-based chemotherapy.

Immunotherapy Shows Early Promise in Advanced Sarcomas

December 7th 2015

Phase Ib/II research has shown promise for adoptive cellular therapy combined with ipilimumab in patients with advanced sarcomas.

Adding Olaratumab to Chemo Improves Survival in Soft Tissue Sarcoma

December 4th 2015

Combining olaratumab with doxorubicin reduced the risk of death by 54% versus doxorubicin alone in patients with advanced soft tissue sarcoma.

Adding Novel Antibody to Pazopanib Shows Promise in Soft Tissue Sarcoma

December 4th 2015

Combining the investigational antibody TRC105 with Votrient showed promising antitumor activity in patients with soft tissue sarcoma.

Dr. Trent on Sequencing Trabectedin for Patients With Soft Tissue Sarcoma

December 2nd 2015

Jonathan C. Trent, MD, associate director for Clinical Research, director of the Sarcoma Medical Research Program at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses sequencing trabectedin (Yondelis) for patients with soft tissue sarcoma.

Emerging Agents Poised to Advance Soft Tissue Sarcoma Care

November 17th 2015

With scores of subtypes and a paucity of molecular markers, soft tissue sarcoma remains a complex and challenging tumor type to treat yet significant strides being made in the field are likely to alter the therapeutic paradigm.

Dr. Philip on Olaratumab for Soft Tissue Sarcoma

November 6th 2015

Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.

Dr. Federman on Ongoing Research in Rare Bone and Soft Tissue Sarcoma

October 28th 2015

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles (UCLA), discusses ongoing research in rare bone and soft tissue sarcoma.

FDA Approves Trabectedin in Soft Tissue Sarcomas

October 23rd 2015

The FDA has approved trabectedin for the treatment of patients with advanced soft tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, who have previously received chemotherapy that included an anthracycline.